Zevra Therapeutics, Inc. Interest Expense
Zevra Therapeutics, Inc. (ZVRA) reported Interest Expense of $735.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-09
- Zevra Therapeutics, Inc. interest expense for the quarter ending 2024-03-31 was $735.00K, a 303.85% increase year-over-year.
- Zevra Therapeutics, Inc. interest expense for the quarter ending 2023-12-31 was $756.00K, a 344.71% increase year-over-year.
- Zevra Therapeutics, Inc. interest expense for the quarter ending 2023-09-30 was $366.00K, a 195.16% increase year-over-year.
- Zevra Therapeutics, Inc. interest expense for the quarter ending 2023-06-30 was $197.00K, a 447.22% increase year-over-year.
- Zevra Therapeutics, Inc. interest expense for fiscal 2023 was $1.50M, a 348.06% increase from fiscal 2022.
- Zevra Therapeutics, Inc. interest expense for fiscal 2022 was $335.00K, a 48.23% increase from fiscal 2021.
- Zevra Therapeutics, Inc. interest expense for fiscal 2021 was $226.00K, a 95.28% decline from fiscal 2020.
- Zevra Therapeutics, Inc. interest expense for fiscal 2020 was $4.79M, a 1.50% decline from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|---|---|
| 2024-03-31 | $735.00K 10-Q · filed 2024-05-09 | $1.49M derived: sum of 2 quarters · filed 2024-05-09 | $1.86M derived: sum of 3 quarters · filed 2024-05-09 | $2.05M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2023-12-31 | $756.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $1.12M derived: sum of 2 quarters · filed 2024-04-01 | $1.32M derived: sum of 3 quarters · filed 2024-04-01 | $1.50M 10-K · filed 2024-04-01 | ||
| 2023-09-30 | $366.00K 10-Q · filed 2023-11-07 | $563.00K derived: sum of 2 quarters · filed 2023-11-07 | $745.00K 10-Q · filed 2023-11-07 | $915.00K derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2023-06-30 | $197.00K 10-Q · filed 2023-08-14 | $379.00K 10-Q · filed 2023-08-14 | $549.00K derived: sum of 3 quarters · filed 2024-05-09 | $673.00K derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2023-03-31 | $182.00K 10-Q · filed 2024-05-09 | $352.00K derived: sum of 2 quarters · filed 2024-05-09 | $476.00K derived: sum of 3 quarters · filed 2024-05-09 | $512.00K derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $170.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $294.00K derived: sum of 2 quarters · filed 2024-04-01 | $330.00K derived: sum of 3 quarters · filed 2024-04-01 | $335.00K 10-K · filed 2024-04-01 | ||
| 2022-09-30 | $124.00K 10-Q · filed 2023-11-07 | $160.00K derived: sum of 2 quarters · filed 2023-11-07 | $165.00K 10-Q · filed 2023-11-07 | $170.00K derived: sum of 4 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $36.00K 10-Q · filed 2023-08-14 | $41.00K 10-Q · filed 2023-08-14 | $46.00K derived: sum of 3 quarters · filed 2023-08-14 | $52.00K derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $5.00K 10-Q · filed 2023-05-15 | $10.00K derived: sum of 2 quarters · filed 2023-05-15 | $16.00K derived: sum of 3 quarters · filed 2023-05-15 | $32.00K derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $11.00K derived: sum of 2 quarters · filed 2023-03-07 | $27.00K derived: sum of 3 quarters · filed 2023-03-07 | $226.00K 10-K · filed 2023-03-07 | ||
| 2021-09-30 | $6.00K 10-Q · filed 2022-11-10 | $22.00K derived: sum of 2 quarters · filed 2022-11-10 | $221.00K 10-Q · filed 2022-11-10 | $1.39M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $16.00K 10-Q · filed 2022-08-12 | $215.00K 10-Q · filed 2022-08-12 | $1.38M derived: sum of 3 quarters · filed 2022-08-12 | $2.54M derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2021-03-31 | $199.00K 10-Q · filed 2022-05-12 | $1.36M derived: sum of 2 quarters · filed 2022-05-12 | $2.53M derived: sum of 3 quarters · filed 2022-05-12 | $3.72M derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $2.33M derived: sum of 2 quarters · filed 2022-03-31 | $3.52M derived: sum of 3 quarters · filed 2022-03-31 | $4.79M 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $1.16M 10-Q · filed 2021-11-10 | $2.36M derived: sum of 2 quarters · filed 2021-11-10 | $3.62M 10-Q · filed 2021-11-10 | $4.81M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $1.20M 10-Q · filed 2021-08-13 | $2.46M 10-Q · filed 2021-08-13 | $3.65M derived: sum of 3 quarters · filed 2021-08-13 | $4.85M derived: sum of 4 quarters · filed 2021-08-13 | ||
| 2020-03-31 | $1.26M 10-Q · filed 2021-05-14 | $2.45M derived: sum of 2 quarters · filed 2021-05-14 | $3.66M derived: sum of 3 quarters · filed 2021-05-14 | $4.89M derived: sum of 4 quarters · filed 2021-05-14 | ||
| 2019-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $2.40M derived: sum of 2 quarters · filed 2021-03-12 | $3.63M derived: sum of 3 quarters · filed 2021-03-12 | $4.86M 10-K · filed 2021-03-12 | ||
| 2019-09-30 | $1.21M 10-Q · filed 2020-10-30 | $2.44M derived: sum of 2 quarters · filed 2020-10-30 | $3.67M 10-Q · filed 2020-10-30 | $4.91M derived: sum of 4 quarters · filed 2020-10-30 | ||
| 2019-06-30 | $1.23M 10-Q · filed 2020-08-12 | $2.46M 10-Q · filed 2020-08-12 | $3.70M derived: sum of 3 quarters · filed 2020-08-12 | $5.07M derived: sum of 4 quarters · filed 2020-08-12 | ||
| 2019-03-31 | $1.23M 10-Q · filed 2020-05-13 | $2.47M derived: sum of 2 quarters · filed 2020-05-13 | $3.84M derived: sum of 3 quarters · filed 2020-05-13 | $5.26M derived: sum of 4 quarters · filed 2020-05-13 | ||
| 2018-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $2.61M derived: sum of 2 quarters · filed 2020-02-28 | $4.03M derived: sum of 3 quarters · filed 2020-02-28 | $5.47M 10-K · filed 2020-02-28 | ||
| 2018-09-30 | $1.37M 10-Q · filed 2019-11-14 | $2.79M derived: sum of 2 quarters · filed 2019-11-14 | $4.23M 10-Q · filed 2019-11-14 | $5.67M derived: sum of 4 quarters · filed 2019-11-14 | ||
| 2018-06-30 | $1.42M 10-Q · filed 2019-08-13 | $2.86M 10-Q · filed 2019-08-13 | $4.30M derived: sum of 3 quarters · filed 2019-08-13 | $5.75M derived: sum of 4 quarters · filed 2019-08-13 | ||
| 2018-03-31 | $1.44M 10-Q · filed 2019-05-14 | $2.89M derived: sum of 2 quarters · filed 2019-05-14 | $4.33M derived: sum of 3 quarters · filed 2019-05-14 | $5.78M derived: sum of 4 quarters · filed 2019-05-14 | ||
| 2017-12-31 | $1.44M 10-K · filed 2018-03-30 | $2.89M derived: sum of 2 quarters · filed 2018-11-09 | $4.33M derived: sum of 3 quarters · filed 2018-11-09 | $5.78M 10-K · filed 2019-03-01 | ||
| 2017-09-30 | $1.45M 10-Q · filed 2018-11-09 | $2.89M derived: sum of 2 quarters · filed 2018-11-09 | $4.33M 10-Q · filed 2018-11-09 | $5.78M derived: sum of 4 quarters · filed 2018-11-09 | ||
| 2017-06-30 | $1.44M 10-Q · filed 2018-08-10 | $2.88M 10-Q · filed 2018-08-10 | $4.33M derived: sum of 3 quarters · filed 2018-08-10 | $5.77M derived: sum of 4 quarters · filed 2018-08-10 | ||
| 2017-03-31 | $1.44M 10-Q · filed 2018-05-11 | $2.89M derived: sum of 2 quarters · filed 2018-05-11 | $4.33M derived: sum of 3 quarters · filed 2018-05-11 | $5.80M derived: sum of 4 quarters · filed 2018-05-11 | ||
| 2016-12-31 | $1.45M 10-K · filed 2018-03-30 | $2.89M derived: sum of 2 quarters · filed 2018-03-30 | $4.36M derived: sum of 3 quarters · filed 2018-03-30 | $5.51M 10-K · filed 2018-03-30 | ||
| 2016-09-30 | $1.44M 10-K · filed 2018-03-30 | $2.92M derived: sum of 2 quarters · filed 2018-03-30 | $4.07M 10-Q · filed 2017-11-09 | $4.76M derived: sum of 4 quarters · filed 2018-03-30 | ||
| 2016-06-30 | $1.48M 10-K · filed 2018-03-30 | $2.63M 10-Q · filed 2017-08-10 | $3.32M derived: sum of 3 quarters · filed 2018-03-30 | $4.01M derived: sum of 4 quarters · filed 2018-03-30 | ||
| 2016-03-31 | $1.15M 10-K · filed 2018-03-30 | $1.85M derived: sum of 2 quarters · filed 2018-03-30 | $2.54M derived: sum of 3 quarters · filed 2018-03-30 | $3.19M derived: sum of 4 quarters · filed 2018-03-30 | ||
| 2015-12-31 | $698.00K 10-K · filed 2017-03-10 | $1.39M derived: sum of 2 quarters · filed 2017-03-10 | $2.04M derived: sum of 3 quarters · filed 2017-03-10 | $2.67M 10-K · filed 2018-03-30 | ||
| 2015-09-30 | $687.00K 10-K · filed 2017-03-10 | $1.34M derived: sum of 2 quarters · filed 2017-03-10 | $1.97M 10-Q · filed 2016-11-10 | $2.60M derived: sum of 4 quarters · filed 2017-03-10 | ||
| 2015-06-30 | $654.00K 10-K · filed 2017-03-10 | $649.00K 10-Q · filed 2015-08-14 | $1.29M 10-Q · filed 2016-08-11 | $1.28M 10-Q · filed 2015-08-14 | $1.92M derived: sum of 3 quarters · filed 2017-03-10 | $2.09M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | $632.00K 10-K · filed 2017-03-10 | $1.26M derived: sum of 2 quarters · filed 2017-03-10 | $1.44M derived: sum of 3 quarters · filed 2017-03-10 | $2.14M derived: sum of 4 quarters · filed 2017-03-10 | ||
| 2014-12-31 | $631.00K 10-K · filed 2016-03-16 | $804.00K derived: sum of 2 quarters · filed 2016-03-16 | $1.51M derived: sum of 3 quarters · filed 2016-03-16 | $1.60M 10-K · filed 2017-03-10 | ||
| 2014-09-30 | $173.00K 10-K · filed 2016-03-16 | $877.00K derived: sum of 2 quarters · filed 2016-03-16 | $974.00K 10-Q · filed 2015-11-13 | |||
| 2014-06-30 | $704.00K 10-K · filed 2016-03-16 | $800.00K 10-Q · filed 2015-08-14 | ||||
| 2014-03-31 | $96.00K 10-K · filed 2016-03-16 | |||||
| 2013-12-31 | $157.00K 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |